Specifying the Anti-inflammatory Effects of Ziltivekimab
Status:
NOT_YET_RECRUITING
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized, double blind, placebo controlled trial is to study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
Phase:
PHASE3
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)